ベガモックス点眼液0.5%
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00218 |
| エビデンスレベル | L5(計算予測のみ) |
| 予測適応症数 | 39 |
| 日本商品名(例) | ベガモックス点眼液0.5%, ベガモックス点眼液0.5%(選), モキシフロキサシン点眼液0.5%「サンド」 |
承認適応症(KEGG)
眼瞼炎、結膜炎
予測適応症(TxGNN)
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | septicemic plague | 99% | DL |
| 2 | hyperamylasemia | 99% | DL |
| 3 | polyclonal hyperviscosity syndrome | 99% | DL |
| 4 | congenital analbuminemia | 99% | DL |
| 5 | blood group incompatibility | 99% | DL |
| 6 | premalignant hematological system disease | 99% | DL |
| 7 | monoclonal gammopathy | 99% | DL |
| 8 | hematological disease associated with an acquired peripheral neuropathy | 99% | DL |
| 9 | congenital hematological disorder | 99% | DL |
| 10 | hematopoietic and lymphoid system neoplasm | 99% | DL |
| 11 | bubonic plague | 99% | DL |
| 12 | endomyometritis | 99% | DL |
| 13 | bronchitis | 99% | DL |
| 14 | urinary tract infection (disease) | 98% | DL |
| 15 | conjunctivitis | 98% | DL |
| 16 | Ureaplasma urethritis | 97% | DL |
| 17 | gonococcal urethritis | 97% | DL |
| 18 | pyelitis | 97% | DL |
| 19 | streptococcal pneumonia | 96% | DL |
| 20 | uterine inflammatory disease | 96% | DL |
| 21 | pyelonephritis | 96% | DL |
| 22 | xanthogranulomatous pyelonephritis | 96% | DL |
| 23 | chronic tubotympanic suppurative otitis media | 96% | DL |
| 24 | cystitis | 96% | DL |
| 25 | L-ferritin deficiency | 96% | DL |
| 26 | acute gonococcal cystitis | 91% | DL |
| 27 | pneumonic plague | 90% | DL |
| 28 | laryngotracheitis | 90% | DL |
| 29 | Klebsiella pneumonia | 89% | DL |
| 30 | staphylococcal pneumonia | 88% | DL |
| 31 | Mycoplasma pneumoniae pneumonia | 86% | DL |
| 32 | pneumonia caused by chlamydia | 83% | DL |
| 33 | streptococcal infection | 74% | DL |
| 34 | peritonitis | 74% | DL |
| 35 | staphylococcus aureus infection | 73% | DL |
| 36 | rhinoscleroma | 60% | DL |
| 37 | bacterial pneumonia | 51% | DL |
| 38 | staphylococcal infection | 7% | DL |
| 39 | plague | 2% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。